Core Insights - Hainan is emerging as a strong magnet for attracting global high-quality resources, particularly in the context of its upcoming customs closure and the opportunities it presents for investment and cooperation [1][6] Group 1: Investment Opportunities - Over 90 companies participated in the "Enterprise Navigation" action in Hainan, with 70 listed companies involved, collectively valued at over 1.6 trillion yuan, focusing on sectors like healthcare, finance, information technology, and electronics [1] - Companies are eager to establish a presence in Hainan ahead of its customs closure, aiming to seize new opportunities for openness and investment [1] - The Wenchang International Aerospace City and other key zones are being explored for their industrial planning and policy advantages, with local authorities actively promoting investment opportunities [3] Group 2: Specific Projects and Initiatives - Wenchang has developed a "4+1" industrial system focusing on high-tech industries, tourism, modern services, and tropical agriculture, with a project list for 2025 that includes 62 projects with a total planned investment of approximately 48.8 billion yuan [3] - A fund of 1 billion yuan is planned to be established in Hainan, targeting key areas such as liquid rocket engine manufacturing and commercial satellite research [3] Group 3: Healthcare Sector Developments - The Boao Lecheng International Medical Tourism Pilot Zone has become a significant entry point for international innovative medical products, benefiting from policies that facilitate rapid clinical application and reduce production costs [5] - An investment of 160 million yuan has been made by Antu Bioengineering in the Haikou National High-tech Zone Innovation Fund, marking the company's initial steps in Hainan [5] - The customs closure is expected to enhance the export capabilities of diagnostic reagents, providing a cost advantage for "Hainan-made" products in Southeast Asian markets [5] Group 4: Talent Development and Policy Expectations - Companies are increasingly focused on the need for skilled talent to support their operations in Hainan, with initiatives aimed at integrating vocational education with key industries [6] - The anticipation of policy benefits related to trade and investment liberalization, cross-border capital flow, and talent mobility is growing among enterprises [6]

Group 1 - The "Listing Company Hainan Tour" event, part of the "Enterprise Navigation" initiative, was launched on October 25 and will last for four days, focusing on key industries such as healthcare, finance, information technology, and electronic manufacturing [1][4]. - Hainan Free Trade Port is attracting more listed companies due to its unique policy advantages and industrial appeal, as highlighted by Yang Zengli, the Party Secretary of Antu Biotech [3][4]. - Antu Biotech, the first listed in vitro diagnostic R&D and manufacturing company in China, has taken its first step in investing in Hainan, aiming to leverage the Free Trade Port's policy advantages for building a "China R&D" hub [4]. Group 2 - Antu Biotech's product range includes immunology, microbiology, biochemistry, molecular diagnostics, and coagulation, with ongoing expansion into sequencing, mass spectrometry, and smart laboratory technologies [4]. - Yang Zengli emphasized the impressive open atmosphere and industrial clustering effect since the establishment of Hainan Free Trade Port, particularly noting the Boao Lecheng International Medical Tourism Pilot Zone's advantages in "licensed drug and device" usage and "zero tariff" policies [4]. - The company has invested in the first government investment fund focused on biomedicine in the Free Trade Port, planning to further develop R&D and industrialization projects, including establishing an innovative product pilot base and reagent manufacturing center [4]. Group 3 - Yang Zengli expressed optimism about the upcoming full closure operation of Hainan Island, which is expected to bring cross-border circulation and cost advantages, allowing the company to export in vitro diagnostic reagents as "Hainan-made" products to Southeast Asia [4]. - Antu Biotech aims to actively connect with local medical institutions and research platforms during the "Listing Company Hainan Tour" to explore specific cooperation paths, anticipating a dual interaction between policy and practice to accelerate local innovative technologies [4].

（文章来源：证券日报） 证券日报网讯 10月24日晚间，安图生物发布公告称，公司于近日收到招商证券股份有限公司（简称"招 商证券"）出具的《关于更换保荐代表人的函》。招商证券为公司2019年公开发行可转换公司债券和 2020年非公开发行股票的保荐人，原指派的保荐代表人为刘海燕、鄢坚。现因刘海燕同志近期职务调 动，不再适合继续履行公司2019年公开发行可转换公司债券和2020年非公开发行股票项目的募集资金专 项持续督导职责。为此，招商证券决定指派张茜同志自2025年10月22日起接替刘海燕同志履行公司2019 年公开发行可转换公司债券和2020年非公开发行股票项目的剩余督导期的保荐工作事宜。 ...

郑州安图生物工程股份有限公司 关于更换保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）于近 日收到招商证券股份有限公司（以下简称"招商证券"）出具的《关于更换保荐 代表人的函》。 招商证券为公司2019年公开发行可转换公司债券和2020年非公开发行股票 的保荐人，原指派的保荐代表人为刘海燕、鄢坚。现因刘海燕同志近期职务调动， 不再适合继续履行公司2019年公开发行可转换公司债券和2020年非公开发行股 票项目的募集资金专项持续督导职责。为此，招商证券决定指派张茜同志自2025 年10月22日起接替刘海燕同志履行公司2019年公开发行可转换公司债券和2020 年非公开发行股票项目的剩余督导期的保荐工作事宜。 本次变更后，公司2019年公开发行可转换公司债券和2020年非公开发行股票 持续督导保荐代表人为鄢坚同志和张茜同志。 证券代码：603658 证券简称：安图生物 公告编号：2025-068 公司董事会对刘海燕同志在担任保荐代表人期间所做的工作表示 ...

Core Viewpoint - The establishment of the Hainan Free Trade Port is expected to enhance companies' access to global R&D resources and deepen international cooperation, particularly benefiting enterprises like Antu Biology in the medical diagnostics sector [1]. Group 1: Company Overview - Antu Biology, listed on the Shanghai Stock Exchange in 2016, is the first publicly traded company in China's in vitro diagnostics sector, focusing on various testing fields including immunology and molecular diagnostics [2]. - The company aims to leverage Hainan's policies in "medical health + technological innovation" to align with its strategic goals [2]. Group 2: Policy Advantages - Key policy advantages include the "special drug and device" policy in the Boao Lecheng International Medical Tourism Pilot Zone, the "zero tariff" benefits of the free trade port, and support for real-world data applications [2]. - Since 2024, 34 batches of medical devices have benefited from tariff exemptions exceeding 8 million yuan, significantly reducing the cost of importing core components for the company [2]. Group 3: Collaboration Opportunities - Three major collaboration opportunities identified include: 1. R&D transformation opportunities through the full-chain service model in the Lecheng Pilot Zone, which can accelerate clinical validation and technology transfer for Antu's high-throughput detection products [3]. 2. Production collaboration opportunities through the "Lecheng R&D + Haikou production" model, facilitating localized production of imported medical devices [3]. 3. Market expansion opportunities driven by the international medical tourism positioning of the Lecheng Pilot Zone, which aligns with the demand for upgraded grassroots medical services in Hainan [3]. Group 4: Investment Initiatives - Antu Biology has initiated its investment strategy by participating in the Haikou National High-tech Zone Innovation Fund, which focuses on biomedicine and has raised 160 million yuan in collaboration with state-owned enterprises [3]. - Future plans include establishing an innovation product pilot base and a reagent manufacturing center to promote "Hainan manufacturing" on the international stage [3]. Group 5: Future Expectations - The upcoming full closure of the Hainan Free Trade Port is viewed as a new opportunity for companies to develop, with expectations to connect with local medical institutions and research platforms for potential technological collaborations [4]. - Confidence in Hainan's ecosystem is bolstered by previous experiences with the Haikou National High-tech Zone Innovation Fund and successful practices within the Lecheng Pilot Zone [5].

Investment Rating - The industry rating is maintained at "Outperform" [2] Core Insights - The in vitro diagnostics (IVD) sector is experiencing a favorable trend in international expansion, with companies accelerating their global strategies. However, the sector faced a decline in revenue and net profit in Q2 2025 compared to the previous year, attributed to various market pressures and policy changes [3][10] - The overall revenue for the A-share IVD sector decreased by 10.0% year-on-year in H1 2025, with net profit down by 17.1% and non-recurring net profit down by 26.3% [3][10] - The gross profit margin for the sector was 57.7% in H1 2025, slightly down from the previous year, primarily due to the impact of medical reform policies [3][10] - The domestic market is facing price declines for IVD products due to intense competition and regulatory changes, creating opportunities for domestic companies to increase market share through import substitution [3][10] - The international market for IVD is significantly larger than China's, with growth potential in emerging markets such as India, Turkey, Russia, and Brazil [3][25] Summary by Sections 1. IVD Mid-Year Report Analysis - The IVD sector's revenue and net profit saw a decline in H1 2025, with a 10.0% drop in revenue and a 17.1% drop in net profit year-on-year [3][10] - The gross profit margin decreased slightly, indicating ongoing cost control efforts amid challenging market conditions [3][10] 2. Subsector Analysis - The immunodiagnostics market remains stable, but the implementation of centralized procurement and DRG policies is slowing growth [17] - High-end technology transformation and international expansion are key strategies for companies to navigate current challenges [17] 3. Related Company Mid-Year Summaries - Mindray Medical reported a revenue of 64.24 billion yuan in H1 2025 for its IVD segment, a decrease of 16.11% year-on-year, but it has a significant opportunity to increase market share due to low penetration rates [10][16] - New Industries achieved a revenue of 21.81 billion yuan in H1 2025, with a slight decline of 1.12%, and is focusing on high-end products to strengthen its market position [10][16] - Aihuilong's self-produced IVD revenue was 6.71 billion yuan, down 14.98%, but it is steadily increasing its installed base of self-produced instruments [10][16]

Market Overview - The Shanghai Composite Index closed at 3916.33 points, above the five-day moving average, with a gain of 1.36% [1] - The total trading volume of A-shares reached 1,892.693 billion yuan [1] Stocks Performance - A total of 1862 A-shares broke through the five-day moving average today [1] - Stocks with significant deviation rates include: - Zhongyu Technology: 22.65% deviation, closing price at 25.07 yuan, with a daily increase of 29.96% [1] - Ligong Guangke: 15.16% deviation, closing price at 30.64 yuan, with a daily increase of 20.02% [1] - Zhengyuan Dixin: 14.72% deviation, closing price at 5.08 yuan, with a daily increase of 20.09% [1] Additional Notable Stocks - Other notable stocks with high daily increases include: - Yunzhong Technology: 20.01% increase, closing price at 36.17 yuan, with a deviation of 12.98% [1] - Guanzhong Ecology: 19.99% increase, closing price at 22.03 yuan, with a deviation of 11.15% [1] - Luqiao Information: 19.63% increase, closing price at 39.68 yuan, with a deviation of 10.88% [1]

Core Points - The company announced the redemption of a structured deposit worth 10 million yuan from Industrial Bank [1] - The decision was made during the board and supervisory meetings held on December 11, 2024, allowing the use of idle raised funds for cash management [1] - The company plans to use up to 1.7 billion yuan from public convertible bonds and 17 billion yuan from private stock issuance for cash management in safe and liquid financial products [1] Redemption Details - On May 28, 2025, the company purchased a large deposit of 10 million yuan using idle funds from a private stock issuance [2] - The deposit matured on October 19, 2025, yielding an interest income of 130,200 yuan, which was returned to the fundraising account on October 20, 2025 [2] Fund Management Overview - The company has been actively managing idle raised funds over the past twelve months, focusing on high-security and liquid financial products [3]

证券代码：603658 证券简称：安图生物 公告编号：2025-067 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次使用闲置募集资金进行现金管理赎回的情况 2025 年 05 月 28 日，公司通过兴业银行郑州商务外环路支行使用非公开发行股 票闲置募集资金购买大额存单 1,000 万元。上述大额存单已于 2025 年 10 月 19 日到 期，公司收到到期本金人民币 1,000 万元，获得利息收益人民币 13.02 万元。上述大 额存单本金和收益于 2025 年 10 月 20 日归还至募集资金账户。 1 本次赎回产品名称：兴业银行可转让单位大额存单 本次赎回金额：1,000 万元 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"） 于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次 会议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同 意公司在确保不影响募集资金投资项 ...

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2][47]. Core Insights - The report highlights that the medical device procurement is gradually reflecting principles of "stabilizing clinical needs, ensuring quality, preventing collusion, and countering price wars" [6][30]. - The report suggests that the recent adjustments in procurement rules indicate a shift towards a more moderate approach, focusing on clinical needs and product quality rather than solely on low prices [6][30]. - The report emphasizes the potential for long-term development in the domestic medical device industry as procurement becomes more reasonable [6][30]. Summary by Sections Industry Overview - The closing index for the medical and biological sector is 8583.87, with a 52-week high of 9323.49 and a low of 6764.34 [2]. Market Performance - During the week of October 13-17, 2025, the A-share medical and biological sector fell by 2.48%, underperforming the CSI 300 index by 0.26 percentage points but outperforming the ChiNext index by 3.23 percentage points [7][36]. - The Hang Seng Healthcare Index decreased by 5.85%, underperforming the Hang Seng Index by 1.88 percentage points [7][36]. Industry Opinions and Investment Recommendations 1. **Innovative Drugs**: The innovative drug sector is experiencing adjustments, with a recommendation to maintain or increase positions based on long-term industry development logic. Key companies to watch include Innovent Biologics, 3SBio, and others [8][21]. 2. **Medical Devices**: The report notes that the National Medical Insurance Administration's recent procurement documents aim to optimize price differences and control "anchor points," indicating a move away from simply selecting the lowest bid [8][29]. 3. **Research Services**: The report expresses optimism about investment opportunities in the research services sector, particularly for companies with strong competitive advantages [26]. Sector Valuation - As of October 17, 2025, the overall valuation of the medical sector (TTM) is 30.03, a decrease of 0.84 from the previous week. The sector's valuation premium over the CSI 300 index is 123.96%, down by 4.90 percentage points [43].